JP Morgan Maintains Overweight on Eli Lilly and Co, Raises Price Target to $900
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Chris Schott maintains an Overweight rating on Eli Lilly and Co (LLY) and raises the price target from $850 to $900.
May 01, 2024 | 2:46 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JP Morgan analyst Chris Schott reaffirmed an Overweight rating on Eli Lilly and Co, increasing the price target from $850 to $900.
The upgrade in the price target by a reputable analyst like Chris Schott from JP Morgan is a strong positive signal for Eli Lilly, suggesting a bullish outlook on the stock's future performance. This could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100